Regentis Biomaterials earnings were -$5.2M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest RGNT earnings report on Jun 30, 2025 announced Q2 2025 earnings of N/A, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, RGNT reported annual earnings of $5.2M, with -226.6% growth.
Regentis Biomaterials Earnings Reports & History FAQ
What were Regentis Biomaterials's earnings last quarter?
Regentis Biomaterials (NYSEMKT: RGNT) reported Q2 2025 earnings per share (EPS) of N/A, up N/A year over year. Total RGNT earnings for the quarter were N/A. In the same quarter last year, Regentis Biomaterials's earnings per share (EPS) was N/A.
Is Regentis Biomaterials profitable or losing money?
As of the last Regentis Biomaterials earnings report, Regentis Biomaterials is currently losing money. Regentis Biomaterials's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$5.20 million, a 181.81% decrease year over year.
What was RGNT's earnings growth in the past year?
As of Regentis Biomaterials's earnings date in Q4 2025, Regentis Biomaterials's earnings has grown year over year. RGNT earnings in the past year totalled -$5.20 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.